Screener
Jazz Pharmaceuticals JAZZ Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Ordinary shares | — | — |
| Non-voting euro deferred shares | 0.1 | 0.1 |
| Capital redemption reserve | 0.5 | 0.5 |
| Additional paid-in capital | 4,243.5 | 4,240.5 |
| Accumulated other comprehensive loss | (651.0) | (568.6) |
| Retained earnings | 939.2 | 646.1 |
| Total shareholders’ equity | 4,532.3 | 4,318.6 |
| Total liabilities and shareholders’ equity | $11,859.6 | $11,659.3 |
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's total equity?
- Jazz Pharmaceuticals (JAZZ) reported total equity of $4.53B in Q1 2026.
- How has Jazz Pharmaceuticals's total equity changed year-over-year?
- Jazz Pharmaceuticals's total equity increased by 8.6% year-over-year, from $4.17B to $4.53B.
- What is the long-term trend for Jazz Pharmaceuticals's total equity?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's total equity has grown at a 3.4% compound annual growth rate (CAGR), from $3.66B to $4.32B.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Jazz Pharmaceuticals's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude